Introduction: Managing biochemical recurrence (BCR) in radiorecurrent prostate cancer remains a significant challenge, with outcomes varying across salvage treatment modalities. This study evaluates the efficacy of various salvage therapies and explores prognostic factors influencing disease progression and survival. Methods: A retrospective review was performed on 81 patients who developed BCR following primary radiotherapy and underwent salvage therapies. Local salvage treatments included salvage radical prostatectomy (n=11), brachytherapy (n=9), stereotactic ablative radiotherapy (SABR, n=8), external beam radiotherapy (EBRT, n=2), and androgen-deprivation therapy (ADT, n=21). Results: During follow-up, 39 patients experienced a second BCR, with a mean interval of 38.52 months from salvage treatment to recurrence. Repeat PSMA PET imaging revealed diverse recurrence patterns: local recurrence only (27%), local and nodal recurrence (2%), local, nodal, and distant recurrence (8%), and distant recurrence only (19%). Systemic therapy was initiated or continued in 30 patients, including androgen receptor pathway inhibitors (ARPI) in 8 cases. Conclusion: This study highlights variability in outcomes across salvage therapies, emphasising the impact of risk stratification and recurrence patterns. The integration of local and systemic therapies, especially in high-risk patients, shows potential to improve oncological outcomes. These findings support the need for individualised treatment strategies to optimise disease control and survival in radiorecurrent prostate cancer patients.